CompletedNCT01328756
Two-Year Safety of Lisdexamfetamine in Children and Teens With ADHD
About this title
Read the official source — NCT01328756Researchers studied Lisdexamfetamine dimesylate, tracking side effects to assess safety and tolerability in children and adolescents with ADHD.
Medication studyAges 6–17Multiple countries
Understand this study
What did researchers investigate?
Researchers studied Lisdexamfetamine dimesylate, tracking side effects to assess safety and tolerability in children and adolescents with ADHD.
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 17 years. Other eligibility criteria applied.
- Listed locations
- Hoboken and 34 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: July 7, 2011
- Recruitment status
- Completed
- Enrollment listed in the registry
- 314
- Sponsor
- Shire
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United Kingdom, Belgium, Germany, ...
- Age range
- From 6 Years to 17 Years
- Official registry ID
- NCT01328756
- Official title
Show the full official title
A Phase 4, Open-Label, Multicentre, Safety Study of Lisdexamfetamine Dimesylate in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Hoboken, Belgium · Leuven, Belgium · Freiburg im Breisgau, Germany
32 more locations
- Mannheim, Germany
- Bamberg, Germany
- Würzburg, Germany
- Hagen, Germany
- Berlin, Germany
- Hamburg, Germany
- Pécs, Hungary
- Szeged, Hungary
- Budapest, Hungary
- Gyula, Hungary
- Cagliari, Italy
- Messina, Italy
- Heerlen, Netherlands
- Bydgoszcz, Poland
- Torun, Poland
- Warsaw, Poland
- Timișoara, Romania
- Bucharest, Romania
- Iași, Romania
- Palma de Mallorca, Spain
- Esplugues de Llobregat, Spain
- Terrassa, Spain
- Torremolinos, Spain
- Pamplona, Spain
- San Cristóbal de La Laguna, Spain
- Badajoz, Spain
- Barcelona, Spain
- Gothenburg, Sweden
- Mölnlycke, Sweden
- Stockholm, Sweden
- Grays, United Kingdom
- Dundee, United Kingdom
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers studied Lisdexamfetamine dimesylate, tracking side effects to assess safety and tolerability in children and adolescents with ADHD.
Who is behind this study?
The study sponsor is Shire.
Did this study involve medication?
Yes. The study involved medication, including Lisdexamfetamine dimesylate.
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 17 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
A 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-onset ADHD
A 6-month, open-label extension to a 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-on...